CG
CRDF icon

Cutler Group’s Cardiff Oncology CRDF Stock Holding History

Cutler Group’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-600
Closed -$3K – 5447
2021
Q3 		$3K Buy
+600
New +$3.77K ﹤0.01% 4777
2018
Q1 		– Sell
-7
Closed – – 4557
2017
Q4 		$0 Sell
7
-3
-30% -$133 ﹤0.01% 5026
2017
Q3 		$0 Sell
10
-5
-33% -$312 ﹤0.01% 5973
2017
Q2 		$1K Buy
+15
New +$966 ﹤0.01% 5818
2017
Q1 		– Sell
-8
Closed -$1K – 6475
2016
Q4 		$1K Sell
8
-41
-84% -$9.57K ﹤0.01% 5923
2016
Q3 		$15K Buy
49
+5
+11% +$1.82K ﹤0.01% 3707
2016
Q2 		$14K Buy
44
+30
+214% +$10.3K ﹤0.01% 3737
2016
Q1 		$4K Buy
+14
New +$4.76K ﹤0.01% 5015

Other funds holding CRDF

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cutler Group's CRDF Position: Q4 2021 in Review

Cutler Group sold out of Cardiff Oncology (CRDF) in Q4 2021, closing a stake of 600 shares — an estimated $3K sold.

Cutler Group first reported a position in CRDF in Q1 2016 and held it in 8 quarters. The position peaked at $15K in Q3 2016. 87 funds tracked by Wall St. Rank hold CRDF as of Q4 2021.

  • Cutler Group reported no remaining Cardiff Oncology position as of Q4 2021 after selling out during the quarter.
  • Cutler Group sold 600 Cardiff Oncology shares in Q4 2021, an estimated $3K.
  • Cutler Group first reported a position in Cardiff Oncology in Q1 2016 and held it in 8 quarters.
  • Cutler Group's Cardiff Oncology position peaked at $15K in Q3 2016.
  • 87 funds tracked by Wall St. Rank held Cardiff Oncology as of Q4 2021.

Based on Cutler Group's 13F filing for Q4 2021, filed 18 Jan 2022.